California would expand state drug supply to insulin and GLP-1s

In California, a new proposal would broaden the state’s hand in the drug market, moving beyond the insulin production program the state already has on the books. The Preventive Treatment Health Care Act would require the California Health and Human Services Agency to expand its partnerships so they also cover insulin and a wider set of glucagon-like peptide-1, or GLP-1, products, including semaglutide, GLP-1 receptor agonists, GIP-plus-GLP-1 tirzepatide and future chronic weight-disease drugs.

The existing program already directs the agency to seek partnerships for generic prescription drug production, including at least one form of insulin made available at production and dispensing costs when no such product already exists in the market. The bill would add a further obligation: the insulin partnership would also have to consider whether the state should guarantee priority access to that supply.

A broader shelf of medicines

The proposal would not stop at a single drug class. It would require the state partnerships to include at least one brand-name prescription drug and the acquisition or production of GLP-1 medicines in multiple forms, including pens, vial injections, pills and patches.

That matters because these are not interchangeable products tucked into the same aisle. Insulin is a daily necessity for many patients with diabetes, while GLP-1 drugs have become central to treatment discussions around obesity and chronic weight disease. The bill is trying to use state purchasing and production power to reach both kinds of care.

The state’s coverage rules stay in the picture

The bill also sits on top of California’s existing coverage requirements for certain health benefit plans and contracts. Rather than creating a separate system from scratch, it would layer a broader supply strategy onto rules the state already uses to shape what those plans and contracts must cover.